Patents by Inventor Douglas Hanahan

Douglas Hanahan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
    Patent number: 7598341
    Abstract: The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: October 6, 2009
    Assignees: Burnham Institue for Medical Research, The Regents of the Universtiy of California
    Inventors: Douglas Hanahan, Erkki Ruoslahti, Johanna A. Joyce, Pirjo Laakkonen
  • LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS
    Publication number: 20070219134
    Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.
    Type: Application
    Filed: February 1, 2007
    Publication date: September 20, 2007
    Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
  • Prefoldin 4 in the treatment and diagnosis of cancer
    Publication number: 20070015724
    Abstract: This invention provides methods employing prefoldin-4 (PFDN-4) nucleic acid and polypeptide sequences to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and/or for prognostic applications. Further, the invention provides methods of identifying inhibitors of PfDN-4 and methods of treating cancer by inhibiting the expression and/or activity of PFDN-4.
    Type: Application
    Filed: June 19, 2006
    Publication date: January 18, 2007
    Applicant: The Regents of the University of California
    Inventors: Joe Gray, Graeme Hodgson, Douglas Hanahan, Jeffrey Hager, Oriol Casanovas
  • Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
    Publication number: 20060002854
    Abstract: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further provides a conjugate containing a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of malignant skin and which includes the amino acid sequence CGKRK (SEQ ID NO: 6) or the amino acid sequence CDTRL (SEQ ID NO: 7), or a conservative variant or peptidomimetic of one of these sequences.
    Type: Application
    Filed: October 20, 2004
    Publication date: January 5, 2006
    Inventors: Douglas Hanahan, Erkki Ruoslahti
  • Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
    Publication number: 20050245445
    Abstract: The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.
    Type: Application
    Filed: October 29, 2004
    Publication date: November 3, 2005
    Inventors: Douglas Hanahan, Erkki Ruoslahti, Johanna Joyce, Pirjo Laakkonen
  • Tumor suppressor genes and their uses
    Publication number: 20040053866
    Abstract: The present invention provides methods of detecting cancer cells in a patient. The methods comprise detecting SXR function in a biological sample from the patient.
    Type: Application
    Filed: August 21, 2002
    Publication date: March 18, 2004
    Applicant: The Regents of the University of California
    Inventors: Jeff Hager, Graeme Hodgson, Douglas Hanahan, Joe Gray
  • Transgenic mice expressing HPV early region oncogene develop progressive cervico-vaginal neoplasia
    Patent number: 5709844
    Abstract: The present invention relates to improved models for progressive epithelial neoplasias and methods for their use. In particular, the invention provides transgenic mice comprising a human papilloma virus early region oncogene operably linked to a promoter which directs expression of the oncogene in a transient amplifying cell in the mice.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 20, 1998
    Assignee: The Regents of the University of California
    Inventors: Jeffrey M. Arbeit, Douglas Hanahan
  • Transgenic mice expressing HPV early region oncogene develop progressive epithelial neoplasia
    Patent number: 5698764
    Abstract: The present invention relates to improved models for progressive epithelial neoplasias and methods for their use. In particular, the invention provides transgenic mice comprising a human papilloma virus early region oncogene operably linked to a promoter which directs expression of the oncogene in a transient amplifying cell in the mice.
    Type: Grant
    Filed: June 9, 1994
    Date of Patent: December 16, 1997
    Assignees: The Regents of the University of California, The United States of America as represented by the Secretary of Health and Human Services
    Inventors: Jeffrey M. Arbeit, Douglas Hanahan, Peter M. Howley
  • Transition in transcriptional activation by intracellular hormone receptors at the tumor stage of dermal fibrosarcoma development
    Patent number: 5631133
    Abstract: Intracellular hormone receptors are discovered to undergo posttranslational regulation. Assays to assess cancer progression and to permit discovery of a new class of biologically active compounds are provided. Related kits are also provided.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: May 20, 1997
    Assignee: The Regents of the University of California
    Inventors: Douglas Hanahan, Keith R. Yamamoto, Maria d. M. Vivanco
  • Biologically pure escherichia coli cell line which is a deoR.sup.- mutant and which is more transformation efficient with foreign plasmids than deoR.sup.+ escherichia coli cell lines, processes for obtaining these cell lines, methods of use
    Patent number: 4851348
    Abstract: A method for obtaining E. coli cell lines which carry the deoR mutation is described, as well as the cell lines themselves. These cell lines are useful in cell transfection and transformation, as they transfect transform at much higher frequencies than the previously available cell lines.
    Type: Grant
    Filed: July 16, 1986
    Date of Patent: July 25, 1989
    Assignee: Cold Spring Harbor Laboratory
    Inventor: Douglas Hanahan